H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
16%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
AmJCaseRep

Annals
ISI-Home

eISSN: 1643-3750

Somatostatin analogues in advanced hepatocellular carcinoma: An updated systematic review and meta-analysis of randomized controlled trials

Xi-Qing Ji, Xin-Jian Ruan, Hong Chen, Gang Chen, Shi-Yong Li, Bo Yu

Med Sci Monit 2011; 17(8): RA169-176

DOI: 10.12659/MSM.881892

Available online: 2011-08-01

Published: 2011-08-01


#881892

Background:    The role of somatostatin analogues in advanced hepatocellular carcinoma (HCC) remains controversial. The aim of this study was to examine the effect of octreotide on the survival of patients with advanced HCC.
    Material/Methods:    Electronic databases including Medline, Embase, Cochrane controlled trials register, Web of Science and PubMed (updated to Dec 2010) and manual bibliographical searches were conducted. A meta-analysis of all randomized controlled trials (RCTs) comparing octreotide versus placebo or no treatment was performed.
    Results:    Eleven RCTs including 802 patients were assessed and 9 were included in the meta-analysis. Meta-analysis showed that the 6-mo and 12-mo survival rates in the octreotide group were significantly higher than those of the control group (6-mo: RR 1.41, 95%CI 1.12–1.77, P=0.003; 12-mo: RR 2.66, 95%CI 1.30–5.44, P=0.008). When including the studies using no treatment as control, with high quality, being performed in China, including >50 patients and with follow-up >2 years, the sensitivity analyses tended to confirm the primary meta-analysis. Whereas, when including the studies using placebo as control or being performed in western countries, the difference was not significant.
    Conclusions:    This meta-analysis demonstrates that octreotide could improve the survival of patients with advanced HCC, but possibly not in western countries. The role of detecting SSTR expression in the administration of octreotide in advanced HCC needs further investigation.

Keywords: Randomized Controlled Trials as Topic, Octreotide - therapeutic use, Liver Neoplasms - pathology, Databases, Factual, Carcinoma, Hepatocellular - pathology, Antineoplastic Agents, Hormonal - therapeutic use, Sensitivity and Specificity, Somatostatin - therapeutic use, Survival Rate



Back